MorphoSys AG
XETRA:MOR
MorphoSys AG
Operating Expenses
MorphoSys AG
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Operating Expenses
-€611.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-25%
|
|
BioNTech SE
NASDAQ:BNTX
|
Operating Expenses
-€2.3B
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Operating Expenses
-€207.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Operating Expenses
-€155.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Operating Expenses
-€174.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
Formycon AG
XETRA:FYB
|
Operating Expenses
-€23.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Operating Expenses?
Operating Expenses
-611.1m
EUR
Based on the financial report for Mar 31, 2024, MorphoSys AG's Operating Expenses amounts to -611.1m EUR.
What is MorphoSys AG's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-25%
Over the last year, the Operating Expenses growth was -33%. The average annual Operating Expenses growth rates for MorphoSys AG have been -25% over the past three years , -37% over the past five years , and -25% over the past ten years .